Ultragenyx Announces U.S. FDA Approval of Dojolvi™ (UX007/triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation DisordersGlobeNewsWire • 06/30/20
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)GlobeNewsWire • 06/18/20
Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus TherapeuticsGlobeNewsWire • 05/21/20
Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) DeficiencyGlobeNewsWire • 05/13/20
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/07/20
GeneTx and Ultragenyx Announce GTX-102 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman SyndromeGlobeNewsWire • 05/04/20
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 04/27/20
Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing TechnologyGlobeNewsWire • 04/01/20
REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic DisorderGlobeNewsWire • 03/31/20
GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman SyndromeGlobeNewsWire • 03/16/20
Ultragenyx (RARE) Down 31.1% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/14/20
Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)GlobeNewsWire • 02/27/20
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/14/20